Answers are grounded in this paper and cite their sources.
The development of chalcones as antimitotic agents has led to the design of other analogues able to interact with tubulin and inhibit its assembly into microtubules. This activity has also been associated with their anti-vascular activity. This review focuses on the development of chalcones and related analogues as antimitotic agents.
No takes yet. Share an insight, caveat, or question.
Sylvie Ducki (2009) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: